Relapsing Multiple Sclerosis clinical trials

Explore recruiting relapsing multiple sclerosis clinical trials.

Recruiting relapsing multiple sclerosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsing Multiple Sclerosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis

Denmark, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis

Sweden, Croatia, Norway, Slovakia, France, Lithuania +17 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE)

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis

Italy, Lithuania, Germany, Poland, France, Latvia +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

P3-IMU-838-RMS-02 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)

Romania, Germany, Estonia, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib

Portugal, France, Italy, Belgium, Greece, Slovakia +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Relapsing Multiple Sclerosis trials by city

Relapsing Multiple Sclerosis in Toronto Relapsing Multiple Sclerosis in Vancouver Relapsing Multiple Sclerosis in Montreal Relapsing Multiple Sclerosis in Calgary Relapsing Multiple Sclerosis in Edmonton Relapsing Multiple Sclerosis in Ottawa Relapsing Multiple Sclerosis in Winnipeg Relapsing Multiple Sclerosis in Quebec City Relapsing Multiple Sclerosis in Hamilton Relapsing Multiple Sclerosis in Kitchener Relapsing Multiple Sclerosis in London Relapsing Multiple Sclerosis in Halifax Relapsing Multiple Sclerosis in New York Relapsing Multiple Sclerosis in Los Angeles Relapsing Multiple Sclerosis in Chicago Relapsing Multiple Sclerosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease